Table 2 |
||||||||
|
Clinical data, IGF-1, and IGFB-3 for Nordic walking group and low-intensity walking group |
||||||||
|
Nordic walking |
Low-intensity walking |
Difference in change between groups at at 15 weeks |
Difference in change between groups at at 30 weeks |
|||||
|
|
||||||||
|
Baseline |
15 weeks to 0 weeks |
30 weeks to 0 weeks |
Baseline |
15 weeks to 0 weeks |
30 weeks to 0 weeks |
|||
|
|
||||||||
|
Median (range) |
Diff median (range) P valuea |
Diff median (range) P valuea |
Median (range) |
Diff median (range) P valuea |
Diff median (range) P valuea |
P valueb |
P valueb |
|
|
|
||||||||
|
Pain threshold kPa |
199.2 (106.2 to 372.3) |
-6.6 (-84.6 to 75.6) P = 0.454 |
13.9 (-109.2 to 94.1) P = 0.278 |
215.4 (105.9 to 380.5) |
-13.7 (-102.1 to 36.8) P = 0.031 |
-12.8 (-165.2 to 108.5) P = 0.689 |
P = 0.169 |
P = 0.339 |
|
|
||||||||
|
Pain mm |
70.5 (7 to 98) |
-0.5 (-40 to 25) P = 0.416 |
-1 (-39 to 53) P = 0.988 |
75 (10 to 92) |
-7 (-27 to 35) P = 0.067 |
-4 (-34 to 29) P = 0.218 |
P = 0.356 |
P = 0.432 |
|
|
||||||||
|
6MWT m |
520 (381 to 660) |
36.5 (-44 to 164.5) P < 0.001 |
29.3 (-150.5 to 145) P = 0.006 |
516 (428 to 656) |
8 (-77 to 107) P = 0.183 |
-2 (-62.5 to 103) P = 0.520 |
P = 0.033 |
P = 0.049 |
|
|
||||||||
|
IGF-1 ng/ml |
4.3 (0 to 15.6) |
-0,2 (-11.4 to 28.7) P = 0.300 |
-0.7 (-12.7 to 1.7) P = 0.019 |
3.3 (0 to 35.7) |
-0.3 (-31.6 to 1.9) P = 0.148 |
-0.1 (-31.2 to 1.4) P = 0.109 |
P = 0.795 |
P = 0.570 |
|
|
||||||||
|
IGFB3 ng/ml |
1,449.2 (546.6 to 3,288.3) |
-57.4 (-1,524.7 to 1,846.6) P = 0.977 |
291.1 (-1,383.3 to 2,821.8) P = 0.426 |
1,680.9 (269.5 to 3,274.2) |
-33.5 (-1551.7 to 1,198.8) P = 0.881 |
242 (-1563 to 1,558.2) P = 0.796 |
P = 0.906 |
P = 0.872 |
|
|
||||||||
|
aWilcoxon signed rank test. bMann-Whitney U test. Median, range (min-max) for baseline, as well as median differences and P values at 15 and 30 weeks, are presented. |
||||||||
|
Bjersing et al. Arthritis Research & Therapy 2012 14:R162 doi:10.1186/ar3902 |
||||||||
